TRANSTHERA-B(02617)has completed the placement of a total of 5.085 million shares, raising approximately HK$282 million net.

TRANSTHERA-B (02617) announcement, all conditions set out in the subscription agreement have been met, and the subscription matters were completed on April 21, 2026. The subscription agent has successfully sold a total of 5.085 million shares of subscription shares to no less than six underwriters at a subscription price of HK$57.03 per share. The 5.085 million shares of subscription shares represent approximately 1.67% of the existing issued H shares and 1.27% of the existing issued share capital before the issuance and enlargement of the issued shares. After the issuance and issuance of subscription shares, they represent approximately 1.65% of the existing issued H shares and approximately 1.26% of the existing issued share capital. The total amount and net amount of proceeds from the subscription matters (after deducting subscription commissions and other related costs and expenses) are approximately HK$290 million and HK$282 million, respectively. Based on this, the net issue price is approximately HK$55.49 per share. The company plans to allocate the net proceeds from the subscription matters (after deducting issuance expenses) as follows: (i) approximately 57% of the net proceeds from the subscription matters will be used for research and development, including clinical development of the company's core product Tinengotinib in late-stage breast cancer, hepatocellular carcinoma, castration-resistant prostate cancer, and TT-00973; (ii) approximately 33% of the net proceeds from the subscription matters will be used for production and commercialization of the company's core product Tinengotinib in China, including the establishment of a commercial team and related marketing activities; and (iii) approximately 10% of the net proceeds from the subscription matters will be used for working capital and general corporate purposes.